{"pmid":32374891,"title":"CONVALESCENT PLASMA TO TREAT CORONAVIRUS DISEASE 2019 (COVID-19): CONSIDERATIONS FOR CLINICAL TRIAL DESIGN.","text":["CONVALESCENT PLASMA TO TREAT CORONAVIRUS DISEASE 2019 (COVID-19): CONSIDERATIONS FOR CLINICAL TRIAL DESIGN.","Transfusion","Barone, Paul","DeSimone, Robert A","32374891"],"journal":"Transfusion","authors":["Barone, Paul","DeSimone, Robert A"],"date":"2020-05-07T11:00:00Z","year":2020,"_id":"32374891","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1111/trf.15843","keywords":["coronavirus infections","plasma","sars virus","severe acute respiratory syndrome"],"topics":["Treatment"],"weight":1,"_version_":1666138496337707008,"score":9.490897,"similar":[{"pmid":32240545,"title":"Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how?","text":["Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how?","Plasma provided by COVID-19 convalescent patients may provide therapeutic relief as the number of COVID-19 cases escalates steeply worldwide. Prior findings in various viral respiratory diseases including SARS-CoV-related pneumonia suggest that convalescent plasma can reduce mortality, although formal proof of efficacy is still lacking. By reducing viral spread early on, such an approach may possibly downplay subsequent immunopathology. Identifying, collecting, qualifying and preparing plasma from convalescent patients with adequate SARS-CoV-2-neutralizing Ab titres in an acute crisis setting may be challenging, although well within the remit of most blood establishments. Careful clinical evaluation should allow to quickly establish whether such passive immunotherapy, administered at early phases of the disease in patients at high risk of deleterious evolution, may reduce the frequency of patient deterioration, and thereby COVID-19 mortality.","Vox Sang","Tiberghien, Pierre","de Lamballerie, Xavier","Morel, Pascal","Gallian, Pierre","Lacombe, Karine","Yazdanpanah, Yazdan","32240545"],"abstract":["Plasma provided by COVID-19 convalescent patients may provide therapeutic relief as the number of COVID-19 cases escalates steeply worldwide. Prior findings in various viral respiratory diseases including SARS-CoV-related pneumonia suggest that convalescent plasma can reduce mortality, although formal proof of efficacy is still lacking. By reducing viral spread early on, such an approach may possibly downplay subsequent immunopathology. Identifying, collecting, qualifying and preparing plasma from convalescent patients with adequate SARS-CoV-2-neutralizing Ab titres in an acute crisis setting may be challenging, although well within the remit of most blood establishments. Careful clinical evaluation should allow to quickly establish whether such passive immunotherapy, administered at early phases of the disease in patients at high risk of deleterious evolution, may reduce the frequency of patient deterioration, and thereby COVID-19 mortality."],"journal":"Vox Sang","authors":["Tiberghien, Pierre","de Lamballerie, Xavier","Morel, Pascal","Gallian, Pierre","Lacombe, Karine","Yazdanpanah, Yazdan"],"date":"2020-04-03T11:00:00Z","year":2020,"_id":"32240545","source":"PubMed","week":"202014|Mar 30 - Apr 05","doi":"10.1111/vox.12926","keywords":["covid-19","antibody","convalescent plasma","infectious disease","plasma"],"topics":["Treatment"],"weight":1,"_version_":1666138490317832194,"score":79.71357},{"pmid":32498762,"title":"Coronavirus Disease 2019: Clinical Review.","text":["Coronavirus Disease 2019: Clinical Review.","INTRODUCTION: In December 2019, an outbreak of pneumonia caused by a novel coronavirus occurred in Wuhan, the capital of Central China's Hubei Province and has been declared a public health emergency of international concern by the World Health Organization since January 2020. MATERIAL AND METHODS: A comprehensive search using the PubMed database was carried out to summarize the latest published information about the epidemiology, definition, pathogenesis, clinical characteristics, treatment options, prognosis and prevention of coronavirus disease 2019. DISCUSSION: This new strain of coronavirus, named severe acute respiratory syndrome coronavirus 2, enters human cells that express angiotensin-converting enzyme II receptors, which exist in the respiratory, gastrointestinal and genitourinary tracts and heart, causing coronavirus disease. Transmission occurs essentially through the respiratory tract and the main symptoms are fever, cough and dyspnea. Diagnosis is based on epidemiological, clinical and imaging features and confirmed by nucleic acid testing. CONCLUSION: Despite intensive research, the exact origin of the virus and pathophysiology of coronavirus disease is not yet completely known, and clinically approved vaccines and drugs that target severe acute respiratory syndrome coronavirus 2 are lacking.","Acta Med Port","Gouveia, Cristina Carvalho","Campos, Luis","32498762"],"abstract":["INTRODUCTION: In December 2019, an outbreak of pneumonia caused by a novel coronavirus occurred in Wuhan, the capital of Central China's Hubei Province and has been declared a public health emergency of international concern by the World Health Organization since January 2020. MATERIAL AND METHODS: A comprehensive search using the PubMed database was carried out to summarize the latest published information about the epidemiology, definition, pathogenesis, clinical characteristics, treatment options, prognosis and prevention of coronavirus disease 2019. DISCUSSION: This new strain of coronavirus, named severe acute respiratory syndrome coronavirus 2, enters human cells that express angiotensin-converting enzyme II receptors, which exist in the respiratory, gastrointestinal and genitourinary tracts and heart, causing coronavirus disease. Transmission occurs essentially through the respiratory tract and the main symptoms are fever, cough and dyspnea. Diagnosis is based on epidemiological, clinical and imaging features and confirmed by nucleic acid testing. CONCLUSION: Despite intensive research, the exact origin of the virus and pathophysiology of coronavirus disease is not yet completely known, and clinically approved vaccines and drugs that target severe acute respiratory syndrome coronavirus 2 are lacking."],"journal":"Acta Med Port","authors":["Gouveia, Cristina Carvalho","Campos, Luis"],"date":"2020-06-06T11:00:00Z","year":2020,"_id":"32498762","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.20344/amp.13957","keywords":["covid-19","coronavirus infections","severe acute respiratory syndrome"],"locations":["Wuhan","Hubei"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Mechanism","Diagnosis"],"weight":1,"_version_":1668804508822536193,"score":64.41086},{"pmid":32423027,"title":"COVID-19: An Update About the Discovery Clinical Trial.","text":["COVID-19: An Update About the Discovery Clinical Trial.","Finding efficacious and safe treatments for COVID-19 emerges as a crucial need in order to control the spread of the pandemic. Whereas plasma therapy attracts much interest, the European project Discovery focuses on the potentialities of small molecules like remdesivir, the combination of lopinavir/ritonavir, hydroxychloroquine, and chloroquine. Results recently published on the clinical evaluation of those drugs are compiled in this brief report, although complete data are still impatiently awaited.","Pharmaceuticals (Basel)","Vanden Eynde, Jean Jacques","32423027"],"abstract":["Finding efficacious and safe treatments for COVID-19 emerges as a crucial need in order to control the spread of the pandemic. Whereas plasma therapy attracts much interest, the European project Discovery focuses on the potentialities of small molecules like remdesivir, the combination of lopinavir/ritonavir, hydroxychloroquine, and chloroquine. Results recently published on the clinical evaluation of those drugs are compiled in this brief report, although complete data are still impatiently awaited."],"journal":"Pharmaceuticals (Basel)","authors":["Vanden Eynde, Jean Jacques"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32423027","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.3390/ph13050098","keywords":["covid-19","sars-cov-2","chloroquine","hydroxychloroquine","lopinavir/ritonavir","plasma","remdesivir"],"e_drugs":["Hydroxychloroquine","lopinavir-ritonavir drug combination","Chloroquine","remdesivir"],"topics":["Treatment"],"weight":1,"_version_":1667252837749358592,"score":64.18179},{"pmid":32502331,"title":"Comparison of confirmed COVID-19 with SARS and MERS cases - Clinical characteristics, laboratory findings, radiographic signs and outcomes: A systematic review and meta-analysis.","text":["Comparison of confirmed COVID-19 with SARS and MERS cases - Clinical characteristics, laboratory findings, radiographic signs and outcomes: A systematic review and meta-analysis.","INTRODUCTION: Within this large-scale study, we compared clinical symptoms, laboratory findings, radiographic signs, and outcomes of COVID-19, SARS, and MERS to find unique features. METHOD: We searched all relevant literature published up to February 28, 2020. Depending on the heterogeneity test, we used either random or fixed-effect models to analyze the appropriateness of the pooled results. Study has been registered in the PROSPERO database (ID 176106). RESULT: Overall 114 articles included in this study; 52 251 COVID-19 confirmed patients (20 studies), 10 037 SARS (51 studies), and 8139 MERS patients (43 studies) were included. The most common symptom was fever; COVID-19 (85.6%, P < .001), SARS (96%, P < .001), and MERS (74%, P < .001), respectively. Analysis showed that 84% of Covid-19 patients, 86% of SARS patients, and 74.7% of MERS patients had an abnormal chest X-ray. The mortality rate in COVID-19 (5.6%, P < .001) was lower than SARS (13%, P < .001) and MERS (35%, P < .001) between all confirmed patients. CONCLUSIONS: At the time of submission, the mortality rate in COVID-19 confirmed cases is lower than in SARS- and MERS-infected patients. Clinical outcomes and findings would be biased by reporting only confirmed cases, and this should be considered when interpreting the data.","Rev Med Virol","Pormohammad, Ali","Ghorbani, Saied","Khatami, Alireza","Farzi, Rana","Baradaran, Behzad","Turner, Diana L","Turner, Raymond J","Bahr, Nathan C","Idrovo, Juan-Pablo","32502331"],"abstract":["INTRODUCTION: Within this large-scale study, we compared clinical symptoms, laboratory findings, radiographic signs, and outcomes of COVID-19, SARS, and MERS to find unique features. METHOD: We searched all relevant literature published up to February 28, 2020. Depending on the heterogeneity test, we used either random or fixed-effect models to analyze the appropriateness of the pooled results. Study has been registered in the PROSPERO database (ID 176106). RESULT: Overall 114 articles included in this study; 52 251 COVID-19 confirmed patients (20 studies), 10 037 SARS (51 studies), and 8139 MERS patients (43 studies) were included. The most common symptom was fever; COVID-19 (85.6%, P < .001), SARS (96%, P < .001), and MERS (74%, P < .001), respectively. Analysis showed that 84% of Covid-19 patients, 86% of SARS patients, and 74.7% of MERS patients had an abnormal chest X-ray. The mortality rate in COVID-19 (5.6%, P < .001) was lower than SARS (13%, P < .001) and MERS (35%, P < .001) between all confirmed patients. CONCLUSIONS: At the time of submission, the mortality rate in COVID-19 confirmed cases is lower than in SARS- and MERS-infected patients. Clinical outcomes and findings would be biased by reporting only confirmed cases, and this should be considered when interpreting the data."],"journal":"Rev Med Virol","authors":["Pormohammad, Ali","Ghorbani, Saied","Khatami, Alireza","Farzi, Rana","Baradaran, Behzad","Turner, Diana L","Turner, Raymond J","Bahr, Nathan C","Idrovo, Juan-Pablo"],"date":"2020-06-06T11:00:00Z","year":2020,"_id":"32502331","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1002/rmv.2112","keywords":["covid-19","middle east respiratory syndrome coronavirus","sars virus","coronavirus","meta-analysis","severe acute respiratory syndrome"],"topics":["Diagnosis"],"weight":1,"_version_":1668804508708241408,"score":56.14939},{"pmid":32412715,"title":"[What is the origin of SARS-CoV-2?]","text":["[What is the origin of SARS-CoV-2?]","Every time a pandemic occurs, dozens of theories emerge to attribute the origin of the event to different facts. The COVID-19 pandemic that has hit virtually all the globe has been no exception. What is known so far about the origin of the virus that causes COVID 19? The first investigations on the origin of this disease have determined that it is a new type of virus, the origin of which is most likely zoonotic.","Rev Med Inst Mex Seguro Soc","Torres-Lopez, Javier","32412715"],"abstract":["Every time a pandemic occurs, dozens of theories emerge to attribute the origin of the event to different facts. The COVID-19 pandemic that has hit virtually all the globe has been no exception. What is known so far about the origin of the virus that causes COVID 19? The first investigations on the origin of this disease have determined that it is a new type of virus, the origin of which is most likely zoonotic."],"journal":"Rev Med Inst Mex Seguro Soc","authors":["Torres-Lopez, Javier"],"date":"2020-05-16T11:00:00Z","year":2020,"_id":"32412715","source":"PubMed","week":"202020|May 11 - May 17","keywords":["coronavirus infections","pandemics","sars virus","virus diseases"],"weight":0,"_version_":1666989866093641728,"score":53.56307}]}